Payment overview · 2025
General Payments
$94.47
5 reported records · 3 companies
Healthcare provider profile · identity verified
Sandra K Mcclure, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WEST LIBERTY, KY · NPI 1760849194
Verified facts
What the public records show
CMS Open Payments records show Sandra K Mcclure, APRN received $94.47 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 57.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.07 | 57.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.44 | 26.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.96 | 15.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.47 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.07 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 235 | 56 |
| Fluconazole | Fluconazole | 153 | 70 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 137 | 79 |
| Omeprazole | Omeprazole | 134 | 38 |
| Prednisone | Prednisone | 123 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 113 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 42 |
| Simvastatin | Simvastatin | 91 | 28 |
| Azithromycin | Azithromycin | 86 | 64 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 33 |
| Ibuprofen | Ibuprofen | 79 | 41 |
| Furosemide | Furosemide | 78 | 26 |
| Losartan Potassium | Losartan Potassium | 75 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 24 |
| Potassium Chloride | Potassium Chloride | 69 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 12 |
| Metformin Hcl | Metformin Hcl | 65 | 21 |
| Meloxicam | Meloxicam | 64 | 21 |
| Ezetimibe | Ezetimibe | 61 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 34 |
| Trazodone Hcl | Trazodone Hcl | 56 | 18 |
| Lovastatin | Lovastatin | 54 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 17 |
| Montelukast Sodium | Montelukast Sodium | 51 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 13 |
| Farxiga | Dapagliflozin Propanediol | 50 | 16 |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Dexamethasone | Dexamethasone | 41 | 30 |
| Cefdinir | Cefdinir | 39 | 25 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Glipizide | Glipizide | 36 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | 12 |
| Glyburide | Glyburide | 32 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 27 | 20 |
| Ozempic | Semaglutide | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 11 |
| Eliquis | Apixaban | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 12 |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.47 · 5 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, TRELEGY ELLIPTA, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error